Clinical Trial Update: Sutimlimab (BIVV009) for the Adult Participants With Cold Agglutinin Disease (CAD) Who Have Completed Phase 3 Studies (CARDINAL or CADENZA) in Japan [Phase 3]

View source ↗

Summary

Clinical trial update indicates that adults with cold agglutinin disease in Japan completed Phase 3 studies of sutimlimab (CARDINAL or CADENZA). Results have be…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cold Agglutinin Disease

Drugs mentioned

• Sutimlimab (sutimlimab)

Snippet

Sponsor: Sanofi | Conditions: Cold Agglutinin Disease | Phase 3 | Status: COMPLETED | Results posted: 2023-10-03